Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial.

Neil E Fleshner Rashid K Sayyid Aaron Richard Hansen Joseph L K Chin Ricardo Fernandes Eric Winquist Theodorus H Van der Kwast Joan Sweet Katherine Lajkosz Miran Kenk Karen Hersey Rosette Veloso Doron Berlin Jaime O Herrera-Caceres Srikala S Sridhar Madeleine Moussa Antonio Finelli Robert J Hamilton Girish S Kulkarni Alexandre R Zlotta Anthony M Joshua

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Neoadjuvant cabazitaxel addition to abiraterone acetate/leuprolide acetate prior to RP did not improve pCR/MRD in clinically localized, high-risk PCa.

Keyphrases

rectal cancer
locally advanced
lymph node
prostate cancer
squamous cell carcinoma
benign prostatic hyperplasia
clinical trial
open label
randomized controlled trial